Adjuvant systemic therapy for breast cancer.

Preview A variety of prognostic factors that offer guidelines for adjuvant systemic therapy must be confronted by breast cancer patients and their physicians. However, many questions regarding the most effective approach remain unanswered. In this article, the authors examine this complex field and review recommendations for posttreatment follow-up.

[1]  R. Love.  Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Redmond,et al.  Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Redmond,et al.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.

[4]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[5]  R. Gelman,et al.  Dose-response in the treatment of breast cancer: a critical review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Redmond,et al.  Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Glick.  Meeting highlights: adjuvant therapy for breast cancer. , 1988, Journal of the National Cancer Institute.

[8]  G. Bonadonna,et al.  The contribution of medicine to the primary treatment of breast cancer. , 1988, Cancer research.

[9]  C. Redmond,et al.  Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. , 1987, Annals of internal medicine.

[10]  Pritchard Ki.  Current status of adjuvant endocrine therapy for resectable breast cancer. , 1987 .

[11]  B. Fisher,et al.  Influence of irradiation of a primary tumor on the labeling index and estrogen receptor index in a distant tumor focus. , 1986, International journal of radiation oncology, biology, physics.

[12]  J. Wittliff.  Steroid‐hormone receptors in breast cancer , 1984, Cancer.

[13]  B. Cheson.  Clinical trials referral resource. Adjuvant therapy of breast cancer. , 1989, Oncology.

[14]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .